



INNOVATIVE, COMBINATORY THERAPIES FOR NEUROMUSCULAR DISEASES

16 MAI 2022 – GENOPOLE – SALLE ELYSEUM

20 rue Henri Desbruères – 91000 Evry-Courcouronnes

10:00 am: **Introduction**

10:10 am: **Session 1. Myopathies**

- The alarmin HMGB1 links oxidative stress and inflammation in muscular dystrophies: a novel therapeutic avenue
Dr. Emilie Vénéreau, Tissue Regeneration and Homeostasis Unit, San Raffaele Scientific Institute, Milan
- Co-administration of Simvastatin does not potentiate the benefit of gene therapy in the mdx mouse model for Duchenne Muscular Dystrophy
Dr. David Israeli, Progressive muscular dystrophies Team, Génethon
- Inclusion body myositis: towards combined therapies?
Pr. François-Jérôme Authier, Centre expert de pathologie neuro-musculaire, CHU Henri Mondor, IMRB, Biologie du système neuromusculaire, Créteil
- Cell therapy of muscular dystrophies: reasons for lack of efficacy and possible solutions
Pr. Giulio Cossu, Cell therapy for myopathies Unit, San Raffaele Scientific Institute, Milan

11:40 am: **Session 2. Neuropathies**

- Stem-cell derived cellular models of Charcot Marie Tooth disease: therapeutic perspectives?
Dr. Nicolas Tricaud, Equipe Maladies des fibres myélinisées, I-Stem
- The development of targeted therapies for Charcot Marie Tooth 1A disease
Dr. Liliane Massade, Thérapies ciblées pour les neuropathies périphériques, U1195 INSERM Maladies et hormones du système nerveux
- Oxysterols/Liver X Receptor: a journey exploring their roles in myelination and the treatment of peripheral neuropathies
Pr. Charbel Massaad, Myelination and Nervous system pathologies, UMR-S1124, INSERM, Université Paris Cité

12:50 am: **Lunch break**

2:00 pm: Session 3. Motor neuron diseases

- Human pluripotent stem cells for neuromuscular diseases
Dr. Cécile Martinat, UMR-S 861, I-Stem
- Combinatory therapeutic innovation for spinal muscular atrophy
Dr. Olivier Biondi, Precision exercises for dystrophies and their therapies, LBEPS, Université Évry Paris-Saclay, Université Paris Cité

3:00 pm: Round Table

Pharmacological, gene, cellular, and physical therapies: how can innovations improve the efficacy of treatments for neuromuscular diseases? Is it possible to foresee the use of identical therapies for different neuromuscular disorders?

Should combinatory approaches be developed? What benefits can be expected?

With the contribution of the speakers and
Pr David Adams, Head of the Neurology Department of the CHU Bicêtre (APHP), coordinator of Nnerf